Studies pressure monitors and activity trackers in adults with pulmonary hypertension
Checks if pressure monitors and activity trackers are safe in adults with pulmonary hypertension.
Plain-language title generated from the registry record
Registry title: Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)
Key facts
- Where
- Sheffield, United KingdomSee the site
Where in United Kingdom
- Sheffield Teaching Hospitals NHS Foundation TrustSheffield, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sheffield Teaching Hospitals NHS Foundation Trust
- Trial code
- NCT04078243
- Record updated
- 25 September 2026
- Original description
Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).Read full original descriptionShow less
Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension.
Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).
Inclusion: Diagnosis of pulmonary hypertension (Group I,II,III and IV); Age 18 years; Estimated glomerular filtration rate (eGFR) > 25; Body mass index (BMI) < 35 (or equivalent); Pulmonary artery (PA) branch 7mm; Negative pregnancy test (If female of childbearing age); Written, informed consent completed; Willingness of the patient to comply.
Exclusion: Active infection; Pulmonary embolus (PE) or deep vein thrombosis (DVT); Cardiac resynchronisation therapy (CRT) device within past 3 months; Mechanical right heart valve; Known coagulation disorder; Known hypersensitivity to aspirin or clopidogrel; Group IV PH; Major cardiovascular event within past 2 months.